Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A

Thrombosis and Haemostasis

Volumn 109, Issue 2, 2013, Pages 248-254

  Ragni, Margaret V ^a,b   Novelli, Enrico M ^a,b   Murshed, Anila ^b   Merricks, Elizabeth P ^c   Kloos, Mark T ^c   Nichols, Timothy C ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Haemophilia A; Recombinant interleukin 11; Von Willebrand disease

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; MESSENGER RNA; RECOMBINANT INTERLEUKIN 11; RISTOCETIN; VON WILLEBRAND FACTOR;

ADULT; ANEMIA; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; FLUID RETENTION; FLUSHING; HEADACHE; HEMOPHILIA A; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; IMMUNOASSAY; INJECTION SITE ERYTHEMA; INSOMNIA; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTE AGGLUTINATION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

ADULT; BIOLOGICAL MARKERS; DEAMINO ARGININE VASOPRESSIN; DRUG RESISTANCE; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOSTATICS; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; PENNSYLVANIA; PROSPECTIVE STUDIES; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84874710907     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-06-0447     Document Type: Article

References (24)

1. Rodeghiero F, Castaman G, Dini E. Epidemiologic investigation of the prevalence of Von Willebrand disease. Blood 1987; 69: 454-459.
2. Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemost 1993; 69: 177-194.
3. Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-2114.
4. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis, and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-174.
5. Nichols WL, Hultin MB, James AH, et al. Von Willebrand Disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart Lung and Blood Institute (NHLBI) Expert Panel Report (USA). Haemophilia 2008; 14: 171-232.
6. Mannucci PM. Desmopressin in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521.
7. Medical Product Safety. In Healthy People 2010: A Systematic Approach to Health Improvement. 2003; 17: 3-19. Available at: http://www.healthypeople. gov. (Accessed February 13, 2012)
8. Isaacs C, Roberts NH, Bailey FA, et al. Randomized placebo-controlled study or recombinant human interleukin-11 to prevent chaemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368-3377.
9. Ragni MV, Jankowitz RC, Chapman HL, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia 2008; 14: 968-977.
10. Ragni MV, Jankowitz RC, Jaworski K, et al. Phase II prospective open label trial of recombinant interleukin-11 (rhIL-11, Neumega®) in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost 2011; 106: 641-645.
11. Haberichter SL, Merricks EP, Fahs SA, et al. Reestablishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood 2005; 105: 145-152.
12. Benson RE, Catalfamo JL, Dodds WJ. A multispecies enzyme-linked immunosorbent assay for von Willebrand factor. J Lab Clin Med 1992; 119: 420-427.
13. Brouland JP, Egan T, Roussi J, et al. In vivo regulation of von Willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler Thromb Vasc Biol 1999; 19: 3055-3062.
14. Nichols TC, Bellinger DA, Reddick RL, et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and haemophilia A. Blood 1993; 81: 2644-2651.
15. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003; 102: 442-448.
16. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, June 14, 2010. Available at: http://ctep.cancer.gov/ forms/CTCAEv4.pdf. (Accessed February 13, 2012)
17. Kaufmann JE, Vischer UM. Cellular mechanisms of the haemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-689.
18. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462.
19. Luxembourg B, Schmitt J, Humpich M, et al Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibri-nogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102: 668-675.
20. Olsen EHN, McCain AS, Merricks EP, et al. Comparative response of plasma VWF in dogs to upregulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood 2003; 102: 436-441.
21. Denis CV, Kwack K, Saffaripour S et al. Interleukin-11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood 2001; 97: 465-472.
22. Gordon MS, McCaskill-Steffens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega, rhIL-11®) in women with breast cancer receiving chaemotherapy. Blood 1996; 87: 3615-3624.
23. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chaemotherapy. Blood 1996; 87: 3607-3614.
24. Ragni MV, Kessler CM. Haemophilia and von Willebrand Disease Subcommittee: Four Randomized Controlled Clinical Trial Concepts. State of the Science Symposium in Transfusion Medicine, Haemostasis and Thrombosis (SoSTMH), National Heart Blood Lung Institute, National Institutes of Health, Bethesda MD, September 14, 2009.